New drug combo shows promise for Tough-to-Treat cancers
NCT ID NCT02495896
First seen Nov 10, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This early-phase study tested a new drug called sEphB4-HSA combined with standard chemotherapy in 61 people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The goal was to find the best dose and check for side effects. Researchers also looked at whether the tumors shrank or stopped growing. This is not a cure, but aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.